Jpmorgan Chase & CO Aerovate Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVTE
# of Institutions
12Shares Held
4.48MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY983KShares$2.63 Million0.0% of portfolio
-
Morgan Stanley New York, NY699KShares$1.87 Million0.0% of portfolio
-
Oup Management Co., LLC604KShares$1.62 Million18.43% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL40KShares$107,3250.0% of portfolio
-
Kovitz Investment Group Partners, LLC24.2KShares$64,8820.0% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $65.5M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...